HIV/AIDS Track Session. Key Points Application of international reference price list during a...

7
HIV/AIDS Track Session

Transcript of HIV/AIDS Track Session. Key Points Application of international reference price list during a...

Page 1: HIV/AIDS Track Session. Key Points Application of international reference price list during a national tender is a valuable tool for achieving optimal.

HIV/AIDS Track Session

Page 2: HIV/AIDS Track Session. Key Points Application of international reference price list during a national tender is a valuable tool for achieving optimal.

Key Points

• Application of international reference price list during a national tender is a valuable tool for achieving optimal pricing in South Africa for ARVs and anti-TB medicines

• Various countries have different information systems with varying level of robustness which affect patient and program monitoring.

• In many countries mostly non-pharmaceutical personnel perform ARV medicine dispensing roles; through task-shifting

• Poor practices and knowledge among health care providers– Low compliance to ART guidelines– Patient education vs Patient counseling

Page 3: HIV/AIDS Track Session. Key Points Application of international reference price list during a national tender is a valuable tool for achieving optimal.

Key Points

• Appointment systems combined with tracking and linkages to home-based care programs promote adherence to keeping appointments for ART/TB care

• Integration of services was found to be feasible and promoted patient outcomes– With chronic diseases (CVD)

• Performance-based reimbursement was associated with good adherence outcomes

Page 4: HIV/AIDS Track Session. Key Points Application of international reference price list during a national tender is a valuable tool for achieving optimal.

Policy Recommendations

• Countries should consider if international price benchmarking is applicable to achieve competitive prices for selected essential medicines, such as ARVs and anti-TB medicines

• For sustainability, low and middle-income countries should integrate ART/TB care into the existing health care systems and services– Other Chronic disease

• ART and TB programs should implement interventions and technologies to improve patient and data management at all levels (as necessary) as it will allow for patient and program monitoring

Page 5: HIV/AIDS Track Session. Key Points Application of international reference price list during a national tender is a valuable tool for achieving optimal.

Policy Recommendations• Adapt standardized indicators , develop and implement

standardized tools for monitoring adherence and retention into the health care system– Countries should develop comprehensive and robust M & E

systems for tracking patient and program performance• Countries should activate and enforce legislation banning the

availability and selling of anti-TB drugs and other antibiotics over the counter (and in – informal outlets).

• Chemoprophylaxis for TB should be shorter and supervised

• Promote patient and public information on HIV/AIDS itself, particularly about successful treatment outcomes and impacting patient behavior– Health and treatment literacy

Page 6: HIV/AIDS Track Session. Key Points Application of international reference price list during a national tender is a valuable tool for achieving optimal.

Key Research Gaps

• What factors make the strategy of international price benchmarking successful and what factors comprise its effectiveness?

• There is need to better define medicines shortages, stock outs and treatment interruptions and to quantify and determine causes using standardized tools and approaches

Page 7: HIV/AIDS Track Session. Key Points Application of international reference price list during a national tender is a valuable tool for achieving optimal.

Key Research Gaps

• What is the drop out rate between HIV testing and initiation of treatment and what interventions can be done to improve Pre- ART patient retention in the system?

• What interventions work at system; facility and individual level in improving patient adherence to treatment and how can these be scaled up?

• What is the best strategy for scaling up technology –based interventions and how do we evaluate the benefit of these interventions vs. the cost?– Integration and sustainability and ROI.